Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Kolltan Pharmaceuticals reports efficacy data from phase Ib KTN-3379 trial

Oct. 21, 2015

OMT and Armo BioSciences enter into anti-PD-1 antibody agreement

Oct. 21, 2015

Inotuzumab ozogamicin receives FDA breakthrough therapy designation for ALL

Oct. 20, 2015

Nordic Nanovector revises clinical development plan for Betalutin

Oct. 16, 2015

First-in-human results presented for personalized immunotherapy

Oct. 16, 2015

Enumeral anti-PD-1 and anti-TIM-3 antibodies may potentiate antitumor immune responses

Oct. 16, 2015

Incyte and Merck & Co. to study the combination of epacadostat with Keytruda

Oct. 14, 2015

Control of CAR T-cell therapy using heterodimerization stimulated by a small molecule

Oct. 13, 2015

Molecular Templates collaborates with MD Anderson Cancer Center on MT-3724

Oct. 13, 2015

Altor receives NCI grant to support development of ALT-803 for NHL

Oct. 9, 2015

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...